Drug Information

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

By

The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.

US Pharmacopeia Revises Chapter on Handling Hazardous Drugs

US Pharmacopeia Revises Chapter on Handling Hazardous Drugs

By

What is the USP and what do I need to know about it as an oncology nurse?

Priority Review of New Drug Application Granted to Apalutamide for CRPC

Priority Review of New Drug Application Granted to Apalutamide for CRPC

By

Data from the phase 3 SPARTAN trial prompted the FDA's Priority Review designation for apalutamide.

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

By

FDA issues black box warning for rolapitant regarding the potential for anaphylaxis, anaphylactic shock, and other hypersensitivity reactions in patients receiving the injectable emulsion for CINV prophylaxis.

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

By

A metabolomics study of the effect of palbociclib/letrozole combination on cancer cells discovered that consumption of foods with certain xenoestrogens has a negative effect on the treatment.

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

By

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

FDA Grants Breakthrough Therapy Designation to Ribociclib for HR+/HER2- Breast Cancer

By

FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

ASHP and Partners Urge Congress to Action on Drug Shortages

ASHP and Partners Urge Congress to Action on Drug Shortages

Groups urge Congress to take immediate action, provide transparency, and improve drug manufacturing.

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.

Opioid Epidemic Response May Be Limiting Cancer-Related Pain Management

Opioid Epidemic Response May Be Limiting Cancer-Related Pain Management

By

A report on current legislation and practice trends regarding opioids and how they are affecting cancer patients' ability to manage their pain.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Alectinib Granted FDA Approval as First-line Therapy for <i>ALK</i>-positive NSCLC

Alectinib Granted FDA Approval as First-line Therapy for ALK-positive NSCLC

By

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

By

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program

By

Why was the ESA APPRISE risk evaluation and mitigation strategy program discontinued?

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

Granulocyte Colony-Stimulating Factors: Use, Administration, Adverse Effects

By

A review of granulocyte colony-stimulating factors, dosage and administration, adverse effects, and nurse management steps is presented.

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Statins, Antihypercholesterolemic Drugs Show Potential as Anticancer Agents

Statins, Antihypercholesterolemic Drugs Show Potential as Anticancer Agents

By

Study results demonstrate that statins have antitumor activity in various solid-tumor cancers and leukemia; however, experts offer these caveats on using them to treat cancer — at least for now.

Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium

Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium

By

A double-blind study compared the effectiveness of lorazepam plus haloperidol with haloperidol alone in reducing agitation in patients with advanced cancer.

Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting

Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting

By

Intractable hiccups can be especially problematic in the advanced cancer and palliative care settings. Dr Thompson, an oncology pharmacist, reviews options for effective medical management of this condition.

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

By

Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.

Median Cost of Cancer Drug Development is Approximately $648 Million

Median Cost of Cancer Drug Development is Approximately $648 Million

Total revenue from sales of 10 drugs was 67.0 billion, with total RD spending of 7.2 billion, researchers found.

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera

By

Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

For adults with relapsed or refractory AML who have an IDH2 genetic mutation

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

By

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Opioid Use Higher Among Cancer Survivors, Even After Long-Term Survivorship

Opioid Use Higher Among Cancer Survivors, Even After Long-Term Survivorship

By

Rates of opioid prescription use is higher among patients with cancer compared with patients who have never had cancer, even after survivorship.

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

By

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

By

Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

By

The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.

New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer

New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer

By

Doses May Be Adjusted for Treating NSCLC Patients

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs